Case Report: Long-Lasting Response in a Patient with Metastatic Renal Cell Cancer Receiving Antitumor Cytotoxic T Lymphocytes. Issue 6 (November 2013)

• Record Type: Journal Article
• Authors: Secondino, Simona; Turin, Ilaria; Montini, Enrica; Porta, Camillo; Maccario, Rita; Pedrazzoli, Paolo; Montagna, Daniela
• Is Part Of: Tumori. Volume 99:Issue 6(2013)
• Page Start: e282
• Page End: e284
• Publication Date: 2013-11
• Subjects: antitumor cytotoxic T lymphocytes -- adoptive immunotherapy -- renal cell carcinoma; Cancer -- Periodicals; 616.994
• DOI: 10.1177/030089161309900620
• Languages: English
• ISSNs: 0300-8916

Abstract

Aims and background: Adoptive immunotherapy can be a therapeutic option to treat cancer patients with advanced-stage disease refractory to conventional therapies. Methods and study design: We used T-cell therapy with autologous antitumor cytotoxic T lymphocytes (CTLs) in a patient with metastatic renal cell carcinoma. Autologous antitumor CTLs obtained by stimulating CD8-enriched cells with dendritic cells pulsed with irradiated apoptotic tumor cells and expanded in vitro were transfused on days +14 and +28 following chemotherapy and every 2 to 4 months thereafter. Results and Conclusions: Treatment with high doses of antitumor CTLs proved to be safe and induced immunological responses and long-lasting clinical benefit in our patient.